New cancer drug enters first human testing
NCT ID NCT06892379
Summary
This is an early-stage study to test the safety and side effects of a new drug called HS-20110 in adults with advanced solid tumors. Researchers will give the drug to participants and closely monitor how their bodies handle it and if it shows any signs of shrinking their tumors. The main goals are to find a safe dose and see if the treatment is tolerable.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BRCR Medical Center INC
RECRUITINGTamarac, Florida, 33321, United States
Contact
-
NEXT Dallas
RECRUITINGIrving, Texas, 75039, United States
Contact
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact
-
SUN YAT-SEN University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Conditions
Explore the condition pages connected to this study.